作者
Urvi Desai, Noam Y Kirson, Andrea Guglielmo, Hoa H Le, Timothy Spittle, Joshua Tseng-Tham, May Shawi, John J Sheehan
发表日期
2021/4
期刊
Journal of Comparative Effectiveness Research
卷号
10
期号
5
页码范围
393-407
出版商
Future Medicine Ltd
简介
Aim
Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK+ oral AD) versus oral AD plus nasal placebo (oral AD+ PBO) among patients with treatment-resistant depression.
Patients & methods
An Excel-based model was developed to estimate the cost-per-remitter for ESK+ oral AD versus oral AD+ PBO over 52 weeks from multiple US payer perspectives. Clinical end points and cost inputs were derived from clinical trials and the literature, respectively.
Results
Under the base-case scenario, the cost-per-remitter for ESK+ oral AD and oral AD+ PBO were as follows: Commercial: US 85,808versusUS 100,198; Medicaid: US 76,236versusUS 96,067; Veteran’s Affairs: US 77,765versusUS 104,519; and Integrated Delivery Network: US 103,924versusUS 142,766.
Conclusion
The findings suggest that ESK+ oral AD is a cost-efficient alternative treatment for treatment-resistant …
学术搜索中的文章
U Desai, NY Kirson, A Guglielmo, HH Le, T Spittle… - Journal of Comparative Effectiveness Research, 2021